

RECEIVED  
CENTRAL FAX CENTER  
JUL 27 2006

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted to the U.S. Patent & Trademark Office  
in accordance with 37 CFR § 1.6(d) on the date indicated.

Karen Zielen  
Name

July 27, 2006  
Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Thomas R. Cech et al.

Filing Date: November 22, 2000

Serial No: 09/721,506

Docket: 015389-002616US; 018-210c

Title: NUCLEIC ACIDS ENCODING HUMAN  
TELOMERASE REVERSE TRANSCRIPTASE  
AND RELATED HOMOLOGS

Art Unit: 1634

Examiner: Bradley L. Sisson, Ph.D.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
ACCOMPANYING A REQUEST FOR CONTINUED EXAMINATION

Commissioner for Patents  
Alexandria VA 22313

Dear Sir,

Applicants acknowledge with gratitude the Advisory Action dated June 21, 2006, indicating that the previous Amendment filed under 37 CFR § 1.116 overcame the rejections previously made under 35 USC § 112 ¶ 1. The only matters to be resolved are rejections for obviousness-type double patenting over other patents and applications owned or co-owned by Geron Corporation.

07/28/2006 TL0111 00000043 071139 09721506  
02 FC:1806 180.00 DA

PATENT  
USSN 09/721,506  
002616US; 018-210c


Accompanying this paper is a Request for Continued Examination under 37 CFR § 1.114. The RCE is being filed to change the title of the apparition, to address the obviousness-type patenting rejections by way of Terminal Disclaimers that will be filed under separate cover, and to remind the Examiner of other issued patents and pending applications related to telomerase reverse transcriptase by way of this Information Disclosure Statement.

The Examiner is requested to consider whether any of the subject matter claimed in the patents and patent applications listed in the accompanying Declaration under 37 CFR § 1.56, or any of the prosecution history in the pending applications listed therein, is material to patentability of any claim in the present application, and to initial the enclosed PTO-1449.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, or that all relevant information has been found.

Accompanying this paper is authorization to charge the deposit account for the RCE. Otherwise, applicants believe that no fee is payable with respect to entry and consideration of this IDS and the accompanying information. However, in the event that the Patent Office determine that another fee is due, the undersigned hereby authorizes the Commissioner to charge the cost of such petitions and other fees due in connection with the filing of these papers to Deposit Account No. 07-1139, referencing the docket number indicated above.

Respectfully submitted,



J. Michael Schiff  
Registration No. 40,253

GERON CORPORATION  
230 Constitution Drive  
Menlo Park, CA 94025  
Telephone: (650) 473-7715  
Fax: (650) 473-8654

July 27, 2006

<b>Form 1449 (modified)</b>  <b>Information Disclosure Statement By Applicant</b>	Filing Date:	November 22, 2000	U.S.S.N.	09/721,506
	Inventors:	T. Cech et al.	Docket:	018/210c
	Title:	Nucleic Acids Encoding Human Telomerase Reverse Transcriptase and Related Homologs	Group:	1634
			Examiner:	Bradley Sisson, Ph.D.

**U.S. Patent Documents**

Examiner Initial	Ref.	Patent No.	Issue or Pub Date	Inventors:	Assignee:	Title:
(none)						

**Foreign Patents and Published Foreign Patent Applications**

Examiner Initial	Ref.	Juris- diction	Document No.	Publication Date	Assignee:	Title:	Trans- lation
(none)							

**Other Documents**

Examiner Initial	Ref.	Author, Title, Date, Source
	HA	Declaration under 37 CFR § 1.56 listing other issued patents and pending applications for telomerase reverse transcriptase.

Examiner	Date Considered
----------	-----------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.